Viriom Successfully Completes Government Contract for Development of Innovative HIV Treatment

Viriom, a member of the ChemRar High-Tech Center, successfully completed the government contract with the Ministry of Industry and Trade of the Russian Federation for developing an innovative drug, a non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus, for treatment of HIV/AIDS and conducting its preclinical and clinical studies.

By signing a licensing agreement with the Swiss company "F. Hoffmann - La Roche", under which Viriom acquired the rights to develop and produce innovative drug VM-1500 for the treatment of HIV/AIDS in Russia and the CIS, Viriom became one of the first companies to receive the support of the Russian Ministry of Industry and Trade for a transfer project within the framework of the Federal Target Program "Development of the pharmaceutical and medical industry of the Russian Federation for the period up to 2020 and beyond." In 2013, an agreement with Roche was expanded, and Viriom received exclusive worldwide rights for the development and commercialization of VM-1500 and its combinations for treatment of HIV/AIDS.

On December 3, 2014 Viriom presented its research results to the Minister of Industry and Trade of the Russian Federation, D. Manturov during the exhibition "PharmMedProm-2014", organized by the Ministry to demonstrate the practical results achieved by the pharmaceutical and medical industries in recent years within the framework of the state program "Development of pharmaceutical and medical industries" for the period from 2013 to 2020.

Photo: Head of HTC ChemRar, Andrey Ivashchenko is presenting VM-1500 to the Head of the Russian Ministry of Industry and Trade, Denis Manturov

Photo: Head of HTC ChemRar, Andrey Ivashchenko is presenting VM-1500 to the Head of the Russian Ministry of Industry and Trade, Denis Manturov

The results of preclinical and clinical studies indicate that the VM-1500 is a new promising candidate for the treatment of patients with HIV infection. To date, four clinical studies have been completed, in which the drug has shown good tolerability, safety and extremely high clinical efficacy.
Viriom is currently conducting a large-scale, multicenter clinical trial of the drug involving HIV-infected patients in 17 research centers in Russia. Interim results from this study confirm the data on the efficacy, tolerability and safety of the drug. 

"Thanks to the support of the Russian Industry and Trade Ministry, we were able to get meaningful scientific evidence of high efficacy and safety of VM-1500. We hope that soon we will be able to bring a modern highly efficient drug for the treatment of HIV infection onto the market. This project will significantly reduce the dependence on expensive foreign drugs, and provide Russian patients with the access to a new standard of care," said Irina Tyrnova, General Manager of Viriom.

About Viriom

Viriom Ltd. is a member of ChemRar group of companies involved in developing innovative antiviral drugs and combinations, treatment methods, and diagnostics. Viriom conducts scientific research in Russia, tapping into the experience and knowledge of Russian scientists, and abroad within the framework of a broad international partnership. The ChemDiv Research Institute is Viriom's major partner in pre-clinical and clinical research. Clinical studies within Russia are conducted at regional centers and on campus of the Moscow City Center for Preventing and Treating AIDS. Among Viriom’s international partners are Roche, Fox Chase Cancer Center (Philadelphia, PA), The Scripps Research Institute (San Diego, CA), Moscow Physics and Technology Institute, and M.P. Chumakov Institute for Poliomyelitis and Viral Encephalitis (Moscow, Russia). The "Viriom" project was approved by the Presidential Commission on Modernization of the Russian Federation. www.viriom.com

Contact Information:

Irina Tyrnova
CEO
LLC Viriom
Phone: +7 495 995 49 44
it@viriom.com